Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 19/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312540 | 0.85 | HCAR2 (0.45) | HCAR2CYP2C9CYP2C8TSHR | |
| SCHEMBL4548365 | 0.78 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL4548410 | 0.78 | HCAR2 (0.59) | HCAR2CYP2C9TSHR | |
| SCHEMBL4548422 | 0.77 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL4548330 | 0.75 | HCAR2 (0.69) | HCAR2CYP2C9CYP2C8 | |
| SCHEMBL4548371 | 0.72 | CYP2C9 (0.62) | HCAR2CYP2C9CYP2C8TSHR | |
| SCHEMBL4548408 | 0.71 | HCAR2 (0.81) | HCAR2CYP2C9 | |
| SCHEMBL4548409 | 0.70 | HCAR2 (0.64) | HCAR2CYP2C9TSHR | |
| SCHEMBL10312506 | 0.70 | HCAR2 (0.54) | HCAR2 | |
| SCHEMBL13920756 | 0.69 | HCAR2 (0.53) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885CYP2C9 1081/4885CYP2C8 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.